Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 5OTHER 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Neuroblastoma 4Ganglioneuroblastoma 4Breast Neoplasms 4Prostatic Neoplasms 3Medulloblastoma 3Wilms Tumor 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Embryonal 2Carcinoma 2Burkitt Lymphoma 2Astrocytoma 2Uterine Cervical Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Seizures 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1

Interventions

Radiotherapy 9Vincristine 8Dactinomycin 8Cyclophosphamide 8Ifosfamide 6Radiation 5Filgrastim 5Doxorubicin 5Irinotecan 4sargramostim 3pegfilgrastim 2brostallicin 2Vinorelbine 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 2Biopsy 2trioctyl phosphine oxide 1perifosine 1lorvotuzumab mertansine 1irinotecan sucrosofate 1imetelstat 1exatecan 1etoposide phosphate 1X-Rays 1Trabectedin 1Topotecan 1Surgical Procedures, Operative 1Spinal Puncture 1Sentinel Lymph Node Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Rhabdomyosarcoma × Magnetic Resonance Spectroscopy × Clear all
NCT04994132 2026-05-05

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Children's Oncology Group

Phase 3 Active not recruiting
118 enrolled
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡